KMO and Huntington disease: Using wild-type and HD model mice, we first determined both the expression and the activity of KMO and measured the levels of the KP metabolites 3-HK and KYNA, in brain tissue after selectively depleting microglia in vivo with the brain-penetrant CSF1R antagonist PLX5622 [24].